Eisai's regional Gary Hendler spoke to PharmaDispatch during a recent trip to Australia, touching on the company's approach to innovation, how governments are attracting industry investment, Eisai's growth in Australia and even its attitude to medicine pricing. …
Eisai's Gary Hendler on Australia, investment and a pragmatic approach to pricing
January 22, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
'Patients can’t wait – swift action and access are the only possible moves from here'
August 26, 2025 - - Latest News -
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech -
Bayer partners with Arrotex to strengthen access to oral contraceptives
August 25, 2025 - - Latest News -
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 - - Latest News -
UK industry cites US pricing ambitions in collapse of new agreement negotiation
August 25, 2025 - - Latest News -
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech